Not currently recruiting at UCLA
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Jay Lee
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Jay Lee
Associate Professor, Surgery, Medicine. Authored (or co-authored) 62 research publications
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)
- ID
- NCT06890598
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 700 study participants
- Last Updated